The supportive care condition center is a comprehensive resource for clinical news and expert insights on supportive care. Read more at OncLive.
November 26th 2024
Manali I. Patel, MD, MPH, MS, details several interventions developed to better serve veterans with cancer who are experiencing economic, social, and geographic barriers to care.
October 30th 2024
The FDA has received an NDA seeking the approval of a 3-month formulation of leuprolide mesylate for advanced prostate cancer.
September 7th 2024
This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.
September 4th 2024
The ASCO Palliative Care Expert Panel has offered recommendations to add health equity measures to their palliative care and other future guidelines.
August 1st 2024
Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, highlight the importance of personalized cannabis use in alleviating treatment-related symptoms.
July 31st 2024
Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, detail a health care cost impacts model pertaining to the use of cannabis for therapy-related symptoms
July 23rd 2024
Crofelemer did not improve the incidence of diarrhea in patients with solid tumors receiving targeted therapy.
June 7th 2024
Defining the goals of a clinical team within a cancer program or oncology practice group, where the focus will be on maximizing QOL, may be difficult.
May 27th 2024
Janet Abrahm, MD, FACP, FAAHPM, reviews the standing of the role of integrative therapies in cancer care.
April 22nd 2024
Adam S. Faye, MD, of NYU Grossman School of Medicine, discusses the epidemiology and treatment for aging patients with inflammatory bowel disease.
April 11th 2024
Richard T. Lee, MD, and Edward S. Kim, MD, MBA, discuss the benefits of integrative oncology and exploring integrative approaches at the Cherng Family Center for Integrative Oncology at City of Hope.
April 2nd 2024
Lindsay Wilde, MD, explains when cannabis may be appropriate and how she’s seen the agent affect quality of life for her patients.
March 29th 2024
Brooke Worster, MD, MS, FACP, and chief medical officer at EO Care, details what oncologists should know about medical cannabis pending the expectant marijuana reclassification from a Schedule I to a Schedule III drug.
March 5th 2024
The FDA has approved the biosimilars denosumab-bddz (Wyost) and denosumab-bddz (Jubbonti) for use in all indications of the reference medicines denosumab (Xgeva) and denosumab (Prolia).
February 28th 2024
The FDA granted an orphan drug designation to LUT014 for the treatment of EGFR inhibitor–induced acneiform rash.
December 26th 2023
The FDA has approved an on-body injector (OBI) presentation of the biosimilar pegfilgrastim-cbqv biosimilar (Udencya), known as Udencya Onbody, which is administered to patients with cancer the day after chemotherapy in order to decrease infection incidence from febrile neutropenia.
June 3rd 2023
The use of talazoparib plus enzalutamide was manageable with dose modifications or standard supportive care treatment in patients with metastatic castration-resistant prostate cancer.
May 18th 2023
Roxadustat proved to be noninferior to recombinant erythropoietin alfa with regard to change in hemoglobin level from baseline to an average level during weeks 9 to 13 in patients receiving concurrent chemotherapy for non-myeloid malignancies in China, meeting the primary end point of an ongoing phase 3 trial.
January 27th 2023
Despite American Society of Clinical Oncology guidelines calling for introduction of palliative care early in the course of disease, these services remain underused.
November 25th 2022
Almost single-handedly, Jennifer Temel, MD, defined a research field in medicine, creating a new focus on quality of life for patients and survivors.